When a child develops Kawasaki disease, rapid treatment becomes essential to protect their heart and blood vessels from lasting damage. This rare inflammatory condition primarily strikes young children, and while its exact cause remains unknown, medical professionals have developed effective approaches to manage symptoms, reduce complications, and support recovery. Understanding the available treatment options—from standard hospital care to innovative therapies being tested in research settings—helps families navigate this challenging diagnosis with greater confidence.

How Treatment Helps Children Recover from Kawasaki Disease

Kawasaki disease treatment focuses on several critical goals. The first priority is bringing down the dangerous inflammation that affects blood vessels throughout the child’s body. This inflammation can weaken vessel walls, particularly in the coronary arteries, which are the blood vessels that supply oxygen-rich blood to the heart muscle. Without prompt intervention, approximately one in four children may develop serious heart complications.^[1][2]

Treatment strategies depend on how quickly the disease is recognized and how the child responds to initial therapy. Most children receive standard treatments that have been proven effective through decades of medical experience. However, some children—up to one-quarter of those diagnosed—do not respond adequately to the first round of treatment. These cases are called refractory Kawasaki disease, and they require additional, more intensive therapeutic approaches.^[15]

The ultimate aim of all treatment is to prevent the formation of coronary artery aneurysms, which are abnormal bulges or weak spots in the artery walls. These aneurysms can lead to blood clots, reduced blood flow to the heart, or even heart attacks in young children. Early treatment dramatically reduces the risk of these complications and improves the child’s long-term outlook.^[3][8]

Beyond protecting the heart, treatment also addresses the uncomfortable symptoms that accompany the disease, such as persistent high fever, rash, red eyes, and swelling of the hands and feet. Managing these symptoms helps the child feel better during recovery and supports the body’s healing process.^[1][5]

Standard Treatment Approaches in the Hospital

Kawasaki disease is always treated in a hospital setting. This allows medical teams to closely monitor the child’s condition, especially the health of their heart, and to respond quickly if complications develop. Treatment typically begins as soon as the diagnosis is confirmed, ideally within the first ten days after fever begins.^[3][10]

The cornerstone of standard treatment involves two main medications: intravenous immunoglobulin (IVIG) and aspirin. IVIG is a solution made from antibodies collected from thousands of healthy blood donors. These antibodies help calm the child’s overactive immune system, which is attacking the blood vessel walls. The standard dose is 2 grams per kilogram of the child’s body weight, given as a single infusion through a vein.^[3][9]

Research has shown that IVIG has a dose-dependent effect, meaning that higher doses given all at once are more effective than smaller doses spread over multiple days. When administered early in the disease course, IVIG significantly reduces inflammation, brings down fever, and—most importantly—lowers the risk of developing coronary artery problems.^[14]

After receiving IVIG, most children show improvement within 36 hours. Their fever drops, they become less irritable, and other symptoms begin to fade. If the fever persists or returns after 36 hours, it suggests that the disease is not responding adequately to treatment, and additional interventions will be needed.^[10]

Aspirin plays a dual role in Kawasaki disease treatment. During the acute phase, when the child still has a fever, aspirin is given at high doses (typically 80 to 100 milligrams per kilogram of body weight per day, divided into four doses). At these levels, aspirin works as an anti-inflammatory medication, helping to reduce swelling in the blood vessels and ease pain. Once the child has been fever-free for 48 to 72 hours, the aspirin dose is lowered.^[9][10]

The low-dose aspirin phase continues for about six to eight weeks after symptoms begin. At this lower dose, aspirin works as an antiplatelet medication, meaning it prevents blood cells called platelets from clumping together to form dangerous blood clots. This is particularly important if the child has developed any coronary artery changes, as clots could block blood flow to the heart.^[9][14]

Throughout the hospital stay and recovery period, children undergo regular heart monitoring. An echocardiogram, which uses sound waves to create moving pictures of the heart, is performed to check the coronary arteries for any signs of damage or aneurysm formation. An electrocardiogram (ECG or EKG) records the heart’s electrical activity to detect rhythm problems. These tests are typically repeated at intervals to track how the heart is responding to treatment.^[9][12]

Most children respond well to this standard treatment combination. Their symptoms improve, inflammation subsides, and they can be discharged from the hospital within a few days to a week. However, careful follow-up continues for weeks and months afterward to ensure complete recovery and to identify any delayed heart complications.^[2][5]

Treatment Options for Refractory Kawasaki Disease

When the initial treatment with IVIG and aspirin does not adequately control the disease, doctors must consider additional therapies. Refractory disease is identified when a child’s fever persists or returns more than 36 hours after completing the first IVIG infusion. This situation occurs in approximately 10 to 25 percent of children with Kawasaki disease.^[15]

The first step for refractory cases is usually to give a second dose of IVIG at the same strength as the first. Many children who did not respond initially will improve after this second infusion. The medical team continues to monitor the child’s temperature, symptoms, and blood markers of inflammation to assess whether the additional IVIG is working.^[3][9]

If the disease remains resistant after two doses of IVIG, doctors turn to other medication options. One approach involves corticosteroids, which are powerful anti-inflammatory drugs. These medications contain hormones that suppress the immune system’s inflammatory response. Corticosteroids can be given intravenously (through a vein) or by mouth, depending on the child’s condition and the doctor’s preference.^[10][15]

Research evidence suggests that corticosteroids may be helpful as additional therapy when used alongside IVIG. Studies have found that children who receive corticosteroids in addition to standard treatment may have a lower chance of developing coronary artery abnormalities. The odds of developing these problems appear to be about 30 percent compared to using IVIG alone, though this benefit varies depending on when and how the corticosteroids are given.^[14]

The most commonly used corticosteroid in Kawasaki disease is methylprednisolone, typically given intravenously for several days. Some doctors may also use oral prednisolone or prednisone as the child’s condition improves. The duration of corticosteroid treatment varies, but it usually lasts from a few days to a couple of weeks, with the dose gradually reduced over time.^[15]

Another treatment option for resistant cases is infliximab, a medication classified as a biologic therapy. Infliximab is an antibody that specifically blocks a protein called tumor necrosis factor alpha (TNF-α), which plays a major role in inflammation. By blocking TNF-α, infliximab helps calm the inflammatory process affecting the blood vessels. This medication is given as a single infusion through a vein.^[15]

Infliximab has shown promise in treating refractory Kawasaki disease, with some studies reporting that it helps reduce fever and inflammation in children who did not respond to IVIG. However, because it is a relatively newer treatment for this condition, doctors typically reserve it for cases that have not improved with IVIG and corticosteroids.^[15]

For particularly difficult cases that continue to resist treatment, doctors may consider other immunosuppressive or anti-inflammatory medications. These include cyclosporin, an immunosuppressive drug that prevents certain immune cells from attacking the blood vessels. Cyclosporin is usually given by mouth and requires careful monitoring because it can affect kidney function and blood pressure.^[15]

In rare, severe cases, doctors might use medications like cyclophosphamide or methotrexate, which are potent immunosuppressive drugs typically used to treat cancer or autoimmune diseases. These powerful medications work by slowing down the overactive immune system that is damaging the blood vessels. Because they can have significant side effects, they are only used when other treatments have failed and the child’s condition is very serious.^[15]

Emerging Therapies Being Studied in Clinical Research

Because Kawasaki disease remains a significant cause of acquired heart disease in children, researchers continue to investigate new and improved treatment approaches. While many of these innovative therapies are still being tested in clinical trials, they represent hope for better outcomes, especially for children with refractory disease.

One area of active research involves refining the use of corticosteroids. Clinical trials are examining whether giving corticosteroids right from the start, along with the first dose of IVIG, might prevent the disease from becoming refractory in the first place. These studies, often conducted as Phase II or Phase III trials, compare the effectiveness of combination therapy against standard IVIG-only treatment. Early results from some trials suggest that this approach might reduce coronary artery complications, but more research is needed to establish clear guidelines.^[14][15]

Researchers are also studying different biologic medications that target specific parts of the immune system involved in Kawasaki disease. Beyond infliximab, which blocks TNF-α, scientists are investigating drugs that block other inflammatory proteins such as interleukin-1 (IL-1) and interleukin-6 (IL-6). These proteins, called cytokines, are chemical messengers that promote inflammation in the body. By blocking them, these medications might more effectively control the inflammatory process.

Clinical trials testing IL-1 blockers and IL-6 blockers are typically Phase I or Phase II studies, meaning they are evaluating the safety of these drugs in children with Kawasaki disease and beginning to assess whether they show signs of effectiveness. The mechanism of action involves these medications binding to the inflammatory proteins or their receptors, preventing them from triggering the inflammatory cascade that damages blood vessels.

Some research centers, including those in the United States, Europe, and Japan, are investigating whether identifying genetic markers or blood biomarkers can help predict which children are most likely to develop refractory disease. If doctors could identify these high-risk children early, they might be able to give them more intensive treatment from the beginning, potentially preventing complications before they occur.

Another innovative approach being explored involves using plasma exchange (also called plasmapheresis), a procedure that filters the blood to remove inflammatory substances and antibodies. This treatment has been used in other inflammatory diseases and is now being tested in small clinical trials for severe, treatment-resistant Kawasaki disease. The procedure involves removing blood from the child, separating out the liquid portion (plasma), treating it or replacing it with donor plasma, and returning the blood to the child’s body.

Researchers are also looking at ways to improve our understanding of why Kawasaki disease happens in the first place. Some studies are investigating whether specific viral or bacterial infections trigger the disease in genetically susceptible children. If the cause can be identified, it might be possible to develop treatments that target the underlying trigger rather than just managing the inflammatory response.

While these investigational therapies offer promise, it is important to understand that they are still being studied. Most are available only within the context of clinical trials at specialized medical centers. Families whose children have particularly difficult or refractory cases might discuss with their doctors whether enrolling in a clinical trial could be an option. Participating in research not only provides access to potentially beneficial new treatments but also contributes to medical knowledge that can help future children with Kawasaki disease.

The locations where these clinical trials take place vary, but major pediatric medical centers in the United States, Europe, and especially in Japan and other Asian countries often lead this research, given that Kawasaki disease is more common in Asian populations. Eligibility for trials typically depends on factors such as the child’s age, disease severity, previous treatments received, and whether there are coronary artery complications.

Most Common Treatment Methods

• Intravenous Immunoglobulin (IVIG)
  • Solution of antibodies from healthy blood donors given through a vein
  • Standard dose is 2 grams per kilogram of body weight as a single infusion
  • Works to calm the overactive immune system attacking blood vessels
  • Most effective when given early in the disease course
  • Significantly reduces risk of coronary artery complications
  • Second dose may be given if fever persists after 36 hours
• Aspirin Therapy
  • High-dose aspirin (80-100 mg/kg/day) during acute fever phase for anti-inflammatory effect
  • Low-dose aspirin continued for 6-8 weeks as antiplatelet therapy
  • Prevents blood clot formation in damaged coronary arteries
  • One of few situations where aspirin is prescribed to young children
  • Dose adjusted based on fever resolution and disease progression
• Corticosteroid Treatment
  • Powerful anti-inflammatory medications containing hormones
  • Methylprednisolone most commonly used, given intravenously
  • May reduce odds of coronary artery abnormalities to about 30% compared to IVIG alone
  • Used for refractory disease not responding to initial IVIG
  • Can also be given alongside IVIG from the start in high-risk cases
  • Treatment duration typically several days to weeks with gradual dose reduction
• Biologic Therapies
  • Infliximab blocks tumor necrosis factor alpha (TNF-α) to reduce inflammation
  • Given as single intravenous infusion for refractory cases
  • Other biologics targeting interleukin-1 and interleukin-6 being studied in clinical trials
  • Work by blocking specific inflammatory proteins involved in blood vessel damage
  • Reserved for cases not responding to standard treatments
• Immunosuppressive Medications
  • Cyclosporin prevents immune cells from attacking blood vessels
  • Cyclophosphamide and methotrexate used in rare, severe refractory cases
  • Work by slowing down overactive immune system
  • Require careful monitoring due to potential side effects
  • Only used when other treatments have failed
• Heart Monitoring and Support
  • Echocardiogram uses sound waves to image coronary arteries and detect aneurysms
  • Electrocardiogram (ECG/EKG) monitors heart’s electrical activity
  • Regular follow-up testing during and after treatment
  • Additional cardiac interventions if severe coronary complications develop
  • Long-term cardiovascular monitoring for children who had artery damage

Managing Recovery and Long-Term Follow-Up

After initial hospital treatment, the journey continues with careful monitoring and follow-up care. Most children who received prompt treatment recover completely within six to eight weeks, though this timeline can vary. During recovery, parents need to watch for any signs that symptoms are returning, such as renewed fever, increased irritability, or changes in the child’s energy level or appetite.^[5][10]

Children continue taking low-dose aspirin for the prescribed period, usually until follow-up echocardiograms confirm that no coronary artery abnormalities have developed. Once ultrasound scans show the heart is healthy and inflammation markers in the blood have returned to normal, aspirin can typically be stopped. However, children who developed coronary artery aneurysms or other heart complications may need to take aspirin or other blood-thinning medications for much longer—sometimes for life.^[9][10]

Follow-up appointments with a pediatric cardiologist (a doctor who specializes in children’s heart conditions) are essential. The frequency and intensity of these appointments depend on whether the child experienced any heart complications. Children without coronary artery changes may need only periodic cardiovascular risk assessment as they grow. Those with persistent aneurysms require more intensive screening, including regular echocardiograms, stress tests, and sometimes other imaging studies.^[17][20]

There is growing awareness that even children who recover without visible coronary artery damage may face a slightly higher risk of developing atherosclerosis (hardening and narrowing of the arteries) later in life. The inflammation that occurred during Kawasaki disease might have left subtle changes in the blood vessel walls. For this reason, doctors recommend that all patients who have had Kawasaki disease maintain healthy lifestyle habits—eating a balanced diet, staying physically active, and avoiding smoking—to protect their cardiovascular health as they age.^[17]

Parents and older children should be educated about the condition so they understand the importance of mentioning their Kawasaki disease history to future healthcare providers. This is particularly important if surgery or other medical procedures are planned, as doctors need to consider the potential for coronary artery issues when planning anesthesia or other aspects of care.^[20]

In very rare cases where coronary artery damage is severe, children may eventually need more intensive heart interventions. These might include cardiac catheterization procedures to open blocked arteries, placement of stents to keep arteries open, or even coronary artery bypass surgery. Such cases are uncommon when Kawasaki disease is diagnosed and treated early, which underscores the importance of recognizing symptoms quickly and seeking immediate medical attention.^[2][8]

The good news is that with current treatment approaches, the vast majority of children with Kawasaki disease recover fully and go on to live normal, healthy lives. Advances in understanding the disease, improvements in diagnostic techniques, and the availability of effective treatments have dramatically improved outcomes over the past several decades. Ongoing research continues to refine treatment strategies and search for even better ways to prevent complications and support complete recovery.